Poster The Joint Annual Meeting of the Stroke Society of Australasia (SSA) and Smartstrokes 2023

An update on the progress of the PERsonalised Knowledge to reduce the risk of Stroke (PERKS-International) randomised controlled trial (#202)

Seana Gall 1 , Valery Feigin 2 , Amanda Thrift 3 , Timothy Kleinig 4 , Dominique Cadilhac 3 5 , Derrick Bennett 6 , Mark Nelson 1 , Tara Purvis 3 , Shabnam Jalili-Moghaddam 2 , Gemma Kitsos 1 , Rita Krishnamurthi 2
  1. Menzies Institute for Medical Research, Hobart, TAS, Australia
  2. NISAN, Auckland University of Technology, Auckland, New Zealand
  3. Faculty of Medicine, Dentistry and Health Sciences, Monash University, Melbourne, Victoria, Australia
  4. Central Adelaide Local Health Network, Adelaide, South Australia
  5. Florey Institute for Neurosciences and Mental Health, Melbourne, Victoria
  6. University of Oxford, Oxford, United Kingdom

Background: The Stroke Riskometer mobile phone app (the App) uses individual demographic, health, and lifestyle data to provide personalised information to modify stroke risk factors. The PERKS-International RCT is testing the App, compared to usual care group not informed about the App, to explore its effectiveness in reducing a stroke risk factor score at 6 months after randomisation.

Aim: To report on progress of recruitment, characteristics of participants and follow-up in this ongoing RCT.

Methods: This Phase III single-blinded endpoint 2 arm RCT is recruiting 790 participants across Australia and New Zealand (5 sites). Inclusion criteria: >35 and ≤75 years, 2+ modifiable risk factors, no history of stroke/CVD/dementia and owns a smartphone. Participants are recruited via social media (Australia + NZ) and primary care (NZ) with self-screening online for eligibility with minimal contact with study staff. Assessments are conducted face-to-face at baseline and 6 months. The primary outcome is a combined behaviour and biomedical stroke risk score (range 0 [no healthy risk factors] to 7 [all healthy risk factors]) at 6 months. We examined (n, %) the completeness of screening, eligibility, randomisation and primary outcome assessment to date.

Results: Recruitment began in Australia in August 2021 and in New Zealand in March 2022. The COVID-19 pandemic has impacted recruitment several times. The screening website has been visited by 2,564 people, with 80% completing screening and 48% eligible to participate. Of those eligible, 504 (41%) people have been randomised with mean (SD) age 58.4 (10.8), 62% women, 65% tertiary educated, and 75% white/European ethnicity. The 6-month primary outcome assessment has been completed by 97% of participants.

Conclusion: Online self-screening requires minimal staff input but only 40% of eligible participants have continued to randomisation. Recruitment will conclude in September 2023 with primary outcome data available in May 2024.